[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Arvinas Inc (ARVN)

Arvinas Inc (ARVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 570,366
  • Shares Outstanding, K 64,521
  • Annual Sales, $ 262,600 K
  • Annual Income, $ -80,800 K
  • EBIT $ -254 M
  • EBITDA $ -257 M
  • 60-Month Beta 1.79
  • Price/Sales 2.17
  • Price/Cash Flow N/A
  • Price/Book 1.48

Options Overview Details

View History
  • Implied Volatility 62.70% (+3.70%)
  • Historical Volatility 41.20%
  • IV Percentile 17%
  • IV Rank 9.31%
  • IV High 219.59% on 02/13/26
  • IV Low 46.60% on 04/06/26
  • Expected Move (DTE 19) 0.90 (10.03%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 71
  • Volume Avg (30-Day) 294
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 6,363
  • Open Int (30-Day) 6,226
  • Expected Range 8.08 to 9.88

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.23
  • Number of Estimates 7
  • High Estimate $1.26
  • Low Estimate $-1.04
  • Prior Year $-0.84
  • Growth Rate Est. (year over year) +72.62%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.37 +7.29%
on 05/19/26
11.40 -21.23%
on 05/01/26
-0.84 (-8.55%)
since 04/29/26
3-Month
8.37 +7.29%
on 05/19/26
14.51 -38.11%
on 03/10/26
-4.29 (-32.33%)
since 02/27/26
52-Week
6.05 +48.31%
on 08/07/25
14.51 -38.11%
on 03/10/26
+1.70 (+23.35%)
since 05/28/25

Most Recent Stories

More News
Arvinas to Present at Jefferies Global Healthcare Conference

NEW HAVEN, Conn., May 29, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced...

ARVN : 8.98 (+1.58%)
Arvinas Employees Give Back During Company-wide Impact Day

NEW HAVEN, Conn., May 18, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to create a new class of drugs based on targeted protein degradation, today...

ARVN : 8.98 (+1.58%)
Arvinas Q1 Earnings Call Highlights

Arvinas (NASDAQ:ARVN) said its first quarter was marked by the FDA approval of VEPPANU, a new licensing agreement with Rigel Pharmaceuticals and continued progress across a clinical-stage pipeline focused...

ARVN : 8.98 (+1.58%)
Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update

– First-ever FDA approved PROTAC supports the further development and potential of Arvinas’ pipeline – – Announced FDA Approval of VEPPANU ™ (vepdegestrant) for the treatment of ESR1m,...

ARVN : 8.98 (+1.58%)
Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

– Arvinas and Pfizer to receive $85 million in upfront and transition payments with potential for additional $320 million in development, regulatory, and commercial milestones and tiered royalites on...

ARVN : 8.98 (+1.58%)
PFE : 26.18 (+0.15%)
Arvinas: Wall Street Bracing for a Miss That May Not Matter

Barchart Research What to Expect from ARVN Earnings ARVN Generated May 6, 2026 Current Price $10.26 EPS Estimate $$-0.95 Consensus Rating Moderate Buy Average Move 7.19% Arvinas: Wall Street Bracing for...

ARVN : 8.98 (+1.58%)
Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026

NEW HAVEN, Conn., May 05, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company working to create a new class of drugs based on targeted protein degradation, today announced...

ARVN : 8.98 (+1.58%)
Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer

– VEPPANU ™ is the first-and-only FDA-approved PROTAC, a type of heterobifunctional protein degrader – – Approval received in advance of FDA-assigned PDUFA date of June 5, 2026; Arvinas and...

ARVN : 8.98 (+1.58%)
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days

– ARV-102 reduced endolysosomal and neuroinflammatory biomarkers implicated in Parkinson’s disease and progressive supranuclear palsy – – ARV-102 was well tolerated across all dose levels...

ARVN : 8.98 (+1.58%)
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders

– Company to highlight new safety, pharmacokinetic, and pharmacodynamic data from Phase 1 clinical trial of ARV-102 in participants with Parkinson’s disease – NEW HAVEN, Conn., March 11, 2026...

ARVN : 8.98 (+1.58%)

Business Summary

Arvinas Inc. is a biopharmaceutical company for patients suffering from debilitating and life-threatening diseases. It engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Arvinas Inc. is based in CT, United States.

See More

Key Turning Points

3rd Resistance Point 9.48
2nd Resistance Point 9.25
1st Resistance Point 9.11
Last Price 8.98
1st Support Level 8.74
2nd Support Level 8.51
3rd Support Level 8.37

See More

52-Week High 14.51
Fibonacci 61.8% 11.28
Fibonacci 50% 10.28
Fibonacci 38.2% 9.28
Last Price 8.98
52-Week Low 6.05

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.